Published in Biotech Business Week, November 27th, 2006
The company expects to launch this new dosage strength in the fourth quarter of 2006. Kadian is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20 mg, 30 mg, 50 mg, 60 mg and 100 mg dosages. The added dosage strength is intended to assist in physicians efforts to individualize their patient's treatments by offering more choices in managing their pain.
The company has conducted in vivo studies to evaluate the interaction of alcohol consumption...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.